Skip to main content
Figure 5 | BMC Psychiatry

Figure 5

From: Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

Figure 5

Rates of overall discontinuation and discontinuation due to efficacy-related reasons by dose group. Figure 5 illustrates the rates of overall discontinuation (NNT = 9 high vs. low dose) and discontinuation for efficacy-related reasons (NNT = 8 high vs. low dose; NNT = 13 high vs. medium dose) by dose group. Efficacy-related reasons includes lack of efficacy and/or any psychiatric adverse event (e.g., "schizophrenia", "paranoid disorder," etc.). Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141).

Back to article page